C

    Coya Therapeutics, Inc. Common Stock (COYA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.56
    -0.03 (-0.65%)

    Market Cap: $107.67M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(9/14)
    Avg Surprise
    -6.57%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.39
    Range$-0.41 - $-0.37
    4 analysts
    EPS Revisions
    1
    0
    7d
    1
    1
    30d
    EPS Estimate Drift
    90d ago$-0.38+2.6%
    60d ago$-0.39+0.0%
    30d ago$-0.39+0.0%
    7d ago$-0.39+0.0%
    Current$-0.39
    Revenue Consensus
    $78570
    Range$0 - $300000
    7 analysts
    Dec 31, 2026
    EPS Consensus$-0.28
    Range$-0.28 - $-0.28
    1 analysts
    Revenue Consensus
    $973450
    Range$45470 - $3M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.28---
    Sep 26EST
    		-$-0.39---
    Jun 26
    		$-0.28$-0.36+22.22%Beat+22.2%
    Mar 26
    		$-0.32N/A+53.87%Beat+27.7%
    Dec 25
    		$-0.34$-0.30-13.33%Miss-88.9%
    Sep 25
    		$-0.13N/A+56.67%Beat+50.0%
    Jun 25
    		$-0.36$-0.43+16.28%Beat-89.5%
    Mar 25
    		$-0.44$-0.12-266.67%Miss-25.7%
    Dec 24
    		$-0.18N/A+55.00%Beat-220.0%
    Sep 24
    		$-0.26$-0.41+36.59%Beat+23.5%
    Jun 24
    		$-0.19$-0.14-35.71%Miss+38.7%
    Mar 24
    		$-0.35$-0.29-20.69%Miss-25.0%
    Dec 23
    		$0.15$0.26-42.31%Miss+148.0%
    Sep 23
    		$-0.34$-0.37+8.11%Beat-70.0%
    Jun 23
    		$-0.31$-0.32+3.13%Beat-
    Mar 23
    		$-0.28$-0.43+34.88%Beat-
    Dec 22
    		$-0.31N/AN/ABeat-
    Sep 22
    		$-0.20$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-4.27EV/EBITDA-6.21x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-270.20%Operating Margin-2890.00%
    ROE-60.50%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio13.40xQuick Ratio13.40x
    Trading Statistics
    Beta0.60Avg Volume114.74K
    52-Week High$7.7552-Week Low$3.71

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.85
    SMA 20$4.76
    SMA 50$4.87
    SMA 200$4.89
    EMA 10$4.77
    EMA 20$4.75
    EMA 50$4.75
    EMA 200$4.97

    MACD

    Line: 0.02Signal: 0.04Hist: -0.01

    ADX

    ADX: 10.7+DI: 19.4-DI: 21.4

    Aroon & PSAR

    Aroon Up80.0
    Aroon Down8.0
    PSAR$5.20

    Bollinger Bands

    Upper Band$5.07
    Lower Band$4.45
    %B Position1298%(Upper)
    Band Width0.17

    RSI (14-Day)

    Neutral
    44.1

    Momentum Oscillators

    Stoch %K20.7
    Stoch %D36.5
    Williams %R-93.3
    ROC (10d)-2.4%
    Momentum-0.11
    CCI (20d)-98.8
    MFI (14d)65.3

    Volatility Measures

    ATR (14d)$0.27(5.9%)
    StdDev (20d)0.15
    Hist Vol46.2%(High)

    Volume Flow

    VWAP$4.58
    OBV-4.0M
    AD Line-5.1M
    CMF (20d)-0.158

    Volume Metrics

    Avg Vol (20d)114.6K
    Vol Ratio0.4x(Low)
    VWMA (20d)$4.75

    Pivot Points

    R3$5.03
    R2$4.92
    R1$4.76
    Pivot Point$4.65
    S1$4.49
    S2$4.38
    S3$4.22

    Advanced Oscillators

    TSI2.63
    Ultimate Osc35.2
    KST40.02

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$243,745$251,147$3.96M$3.56M$163,616$257,884$1,952$0$3.43M$126,838$6.00M$0
    Cost of Revenue$0$0$-5,200,395$0$0$0$1.94M$0$0$0$1.61M$0
    Gross Profit$243,745$251,147$3.96M$3.56M$163,616$257,884$1,952$0$3.43M$126,838$6.00M$0
    Operating Expenses$7.29M$7.89M$9.99M$6.00M$6.58M$7.93M$4.08M$4.45M$6.66M$5.61M$4.19M$3.56M
    R&D$5.03M$4.11M$6.71M$3.43M$3.66M$5.21M$1.94M$2.22M$4.57M$3.16M$1.80M$1.59M
    SG&A$2.26M$3.78M$3.27M$2.56M$2.91M$2.71M$2.14M$2.22M$2.09M$2.44M$2.38M$1.96M
    Operating Income$-7,046,988$-7,640,217$-6,030,888$-2,432,897$-6,414,518$-7,676,922$-4,080,295$-4,450,289$-3,236,125$-5,483,002$1.82M$-3,564,063
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$1.79M$0$0$0$3.58M$0$0$0$0$0
    Income Before Tax$-6,638,260$-7,206,990$-7,821,284$0$-6,094,977$-7,306,757$-7,657,481$0$-2,891,680$-5,051,913$2.29M$-3,564,063
    Income Tax Expense$0$0$3,089$0$0$0$-720,287$0$0$0$0$0
    Net Income$-6,638,260$-7,206,990$-5,708,542$-2,115,831$-6,094,977$-7,306,757$-2,915,776$-4,021,418$-2,891,680$-5,051,913$1.27M$-3,421,974
    EBITDA$-6,635,453$-7,204,183$-5,698,612$-2,108,991$-6,088,137$-7,299,917$-3,629,223$-4,014,577$-2,884,840$-5,045,073$2.30M$-3,557,222
    EBIT$-6,638,260$-7,206,990$-5,705,453$-2,115,831$-6,094,977$-7,306,757$-3,636,063$-4,021,418$-2,891,680$-5,051,913$2.29M$-3,564,063
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about COYA

    News

    Coya Therapeutics Advances Phase 2 ALSTARS ALS Trial Toward 2026 Enrollment Finish

    Coya Therapeutics is progressing its Phase 2 ALSTARS trial for amyotrophic lateral sclerosis (ALS), with enrollment expected to conclude in 2026 and topline data anticipated in Q1 2027. The company's lead candidate, COYA 302, aims to modulate regulatory T cells and inflammation. Analysts maintain "Buy" ratings for COYA, citing its cash runway and potential in addressing an unmet medical need for ALS patients.

    Streetwise Reports•8/26/26•
    Somewhat-Bullish

    H.C. Wainwright reiterates Coya Therapeutics stock rating at buy By Investing.com

    H.C. Wainwright has reiterated a Buy rating on Coya Therapeutics (NASDAQ:COYA) with an $18.00 price target, noting the stock's potential undervaluation and strong cash position relative to debt. The firm highlights Coya Therapeutics' advanced clinical pipeline, including the ALSTARS Phase 2 trial for ALS and a planned Phase 2a study for frontotemporal dementia, with key data releases expected in 2026 and 2027. Another firm, Roth/MKM, also initiated coverage with a Buy rating and a $12.00 price target, based on promising early data for COYA 302 and anticipated conditional approval by early 2028.

    Investing.com Canada•8/24/26•
    Bullish

    Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

    Coya Therapeutics (NASDAQ:COYA) has received a consensus "Moderate Buy" rating from seven brokerages, with an average 12-month price target of $15.33, significantly higher than its current $4.86. The clinical-stage biotechnology company recently surpassed earnings expectations, reporting a smaller adjusted loss and higher revenue than anticipated. Despite being unprofitable with a negative net margin, institutional investors and hedge funds hold a notable stake of approximately 39.75% in the company.

    MarketBeat•8/21/26•
    Somewhat-Bullish

    Chardan Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA)

    Chardan Capital has reiterated its "Buy" rating for Coya Therapeutics (NASDAQ:COYA) and set a $14 price target, indicating a potential 192% upside. Analyst sentiment for the stock is generally positive, with a "Moderate Buy" consensus and an average price target of $15.33. The company recently reported better-than-expected quarterly earnings and revenue, and institutional investors hold nearly 40% of its stock.

    MarketBeat•8/12/26•
    Bullish

    Coya Therapeutics (NASDAQ:COYA) Posts Earnings Results, Beats Estimates By $0.08 EPS

    Coya Therapeutics (NASDAQ:COYA) reported a quarterly loss of $0.28 per share, surpassing analyst expectations by $0.08. Despite beating estimates, the company showed negative net margins and return on equity, with shares rising 0.6% during Tuesday trading. Analysts maintain a "Moderate Buy" consensus, and institutional investors hold a significant stake in the company.

    MarketBeat•8/11/26•
    Somewhat-Bullish

    Frequently Asked Questions About COYA

    Does COYA pay dividends?
    Coya Therapeutics, Inc. Common Stock (COYA) does not currently pay a regular dividend.
    What is COYA's market cap?
    Coya Therapeutics, Inc. Common Stock (COYA) has a market capitalization of $107.67M with a current stock price of $4.56.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In